Harvard Pilgrim Health Care Home
  HPHConnect
 
  Learn more.
  Sign up for HPHConnect.
Medical Management
E-Transactions
HPHConnect
Pharmacy
For Your Patient
News Center
Network Matters
Newsletter Archives
Newsletter Registration
Newsroom
Office Support
Products
Provider Manual
Medicare Advantage
Research & Teaching
Resources & Links
 
Print    Text Size

Network Matters
News and Information for the
Harvard Pilgrim Health Care Network

November 2014

Prior Authorization on Select Opioid Analgesics 


Beginning next year, Harvard Pilgrim will require prior authorization on a select number of opioid analgesics used to manage moderate to severe chronic pain. Because there is a risk of addiction, abuse, and misuse with these medications, careful management is necessary. Given the heightened awareness of opioid abuse at the state level, Harvard Pilgrim is implementing these prior authorization requirements as an addition to our opioid management program.

Harvard Pilgrim is not requiring any members currently taking these medications who have a presumed cancer diagnosis (as determined by ICD-9 code or medication history) to obtain prior authorization.

However, any members beginning treatment with opioid analgesics or members currently taking these medications who have not been diagnosed with cancer will require prior authorization beginning next year. Earlier this month, Harvard Pilgrim mailed letters to the few members who had filled prescriptions for these medications within the last 6 months who do not have a cancer diagnosis to notify them of the new prior authorization requirements.

Zohydro

Effective Jan. 1, 2015, Zohydro ER, a long-acting hydrocodone product that is not formulated with abuse-deterrent mechanisms, will require a prior authorization on the Harvard Pilgrim’s Premium (open) formulary. Zohydro ER is not covered on our Value (closed) formulary or the 2015 Medicare Advantage formulary.

Transmucosal immediate-release fentanyl products

Also beginning on Jan. 1, 2015, Harvard Pilgrim will require prior authorization on all transmucosal immediate-release fentanyl products (for example, fentanyl citrate lozenges, Fentora, and Subsys) for all formularies (Value, Premium, and Medicare Advantage). These products are used to manage breakthrough pain in patients with cancer who are 18 years of age and older and are already receiving, and are tolerant to, around-the-clock opioid therapy for their underlying, persistent cancer pain.

Requesting prior authorization

To request prior authorization for any of the medications listed above, please review the clinical criteria and submit the appropriate Medication Request Form by fax to MedImpact Healthcare Systems at 888-807-6643. The clinical criteria and medication request form will be available on the prior authorization section of our Pharmacy webpage by Dec. 15.

Email this article to a colleague   


Network Matters Archives

Download printer-friendly version

HPHCURRENT EVENTS

Join Us for the Mobile Farmers’ Market in Hartford

Let’s Go! Healthcare Launches Childhood Obesity Webinar Series

New WeighingIn Blog Creates an Online Community of Nutrition and Obesity Prevention Experts

CLINICIAN CORNER

Harvard Pilgrim Offers Reports to Help Improve Medication Adherence

Reminder: Value Formulary Offered in 2015

Prior Authorization on Select Opioid Analgesics

Reminder: Use of Non-Participating Ambulance Providers

OFFICE ASSISTANT

A New Alliance: Health Plans, Inc. and UnitedHealthcare

PUBLICATION INFORMATION

Eric H. Schultz,
President and Chief Executive Officer

Richard Weisblatt PhD,
Senior Vice President, Provider Network

Annmarie Dadoly,
Editor

Kristin Edmonston,
Production Coordinator